The above data demonstrate that MPZL3-deficient cells may be less susceptible to DNA damage and apoptosis and that this could contribute to decreased cisplatin chemosensitivity in some ovarian cancer cell lines. Here, MPZL3 is linked to ovarian carcinoma.